We are live on ! Find out more

Kura Oncology

KURA

Market cap $1.01B

11.39 USD

-0.18

1.56%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

11.52

+0.13

1.14%

1 day

-1.56%

5 days

-11.98%

1 month

14.7%

3 months

28.56%

6 months

23.54%

Year to date

10.15%

1 year

28.99%

5 years

-42.96%

10 years

86.42%

About: Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Employees: 260

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 29.2%

Neutral 70.8%

Negative 0%

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral presentation at European Association for the Study of Diabetes (EASD) Annual Meeting on September 29, 2026 – – Separately financed subsidiary provides dedicated capital and leadership to advance KO-7246 through initial clinical proof of concept while Kura retains a substantial ownership stake in Caspian, representing approximately half of the company on a fully diluted basis, and remains focused on oncology – SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the launch of Caspian Therapeutics, Inc. (“Caspian”), a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases.

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026.

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

Kura Oncology to Participate in Three Investor Conferences in September

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m.

Kura Oncology to Participate in Three Investor Conferences in September

Zacks Investment Research

Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects

Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early commercial performance in relapsed/refractory NPM1-mutated AML. The company achieved $9.1M net product revenue in two quarters, marking a 57% sequential increase, and targets significant market expansion via first-line AML indications. Phase 3 KOMET-017 trial topline data in 2028 and two phase 1b KOMET-007 data readouts in 2H 2026 are key catalysts for pipeline expansion and valuation.

Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects

The Motley Fool

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?

The President and CEO acquired ~100,000 shares at $12.39 per share for a total transaction value of $1.2 million. The purchase increased the executive's total equity holdings by 9%.

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?

Zacks Investment Research

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?

Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?

See News Rankings

Price charts implemented using Lightweight Charts™